Nuclear medicine and biology最新文献

{"title":"PET imaging of [64Cu]copper(II) chloride and tetrathiomolybdate administration in animal models of triple-negative breast cancer","authors":"Michael R. Lewis ,&nbsp;Claudia G. Chambers ,&nbsp;Maryam Heidari-Kharaji ,&nbsp;Kanishka Sikligar ,&nbsp;Vivian A. Yang ,&nbsp;Alexander W. Schaedler ,&nbsp;Mojgan Golzy ,&nbsp;Lisa D. Watkinson ,&nbsp;Terry L. Carmack ,&nbsp;Joni M. Lunceford ,&nbsp;Colleen Garrett ,&nbsp;Christos Papageorgiou ,&nbsp;Jessica L. Talbott ,&nbsp;Charles A. Maitz ,&nbsp;Jeffrey N. Bryan ,&nbsp;Charles J. Smith","doi":"10.1016/j.nucmedbio.2025.109596","DOIUrl":"10.1016/j.nucmedbio.2025.109596","url":null,"abstract":"<div><h3>Background</h3><div>In the United States, breast cancer is the second leading cause of cancer-related death. Triple-negative breast cancer (TNBC) is of substantial concern, as it lacks the receptors usually targeted by conventional treatments. Triple-negative breast tumors have a high degree of copper metabolism for the synthesis of transporters, enzymes, and chaperones. Tetrathiomolybdate (TM) is a well-tolerated oral therapy that has been investigated for chelating copper from tumors in TNBC patients, resulting in extended remission. The overall goal of this research was to evaluate [⁶⁴Cu]CuCl₂ PET/CT imaging of copper utilization in this disease, in the presence and absence of TM.</div></div><div><h3>Methods</h3><div>Uptake, internalization, and efflux studies were performed in TNBC cells versus normal cells. Biodistribution experiments were then conducted in TNBC xenograft-bearing mice that were administered TM versus controls. PET/CT imaging of mice carrying TNBC tumors was also performed in the presence and absence of TM. Finally, imaging was performed in a healthy cat and in a cat with mammary carcinoma.</div></div><div><h3>Results</h3><div>SUM149 TNBC cells selectively took up, internalized, and retained [⁶⁴Cu]CuCl₂ more avidly than normal fibroblasts. When SUM149-bearing mice were given TM, tumor uptake decreased and tracer accumulation shifted predominantly to the liver and kidneys, compared to control mice, in which large quantities of ⁶⁴Cu were excreted into the intestines. These results were supported by PET/CT imaging of the mice. PET/CT of companion cats gave results similar to those obtained in mice, with high accumulation of radioactivity observed in the liver and gallbladder and moderate intestinal and renal clearance. In a cat with mammary carcinoma, tumor uptake of [⁶⁴Cu]CuCl₂ was highly conspicuous, even in close proximity to the liver.</div></div><div><h3>Conclusions</h3><div>Utilization of [⁶⁴Cu]CuCl₂ in triple-negative breast cancer can be detected efficiently in cell and animal models of this disease. The tracer was also used successfully to evaluate TM administration in the SUM149 TNBC mouse model. Furthermore, PET/CT imaging of both mice and cats with breast cancer shows the potential to monitor treatment with TM in a facile, noninvasive manner. We are currently conducting a clinical trial of [⁶⁴Cu]CuCl₂ PET/CT in companion cats with mammary carcinoma, with the future goal of evaluating the efficacy of TM in feline patients.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109596"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of concern “cross sections of the 226Ra(p,xn) reactions relevant for 225Ac production“","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109598"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scandium-47 as a radionuclide precursor: Feasibility of production in a 47Ca/47Sc generator-like system","authors":"Izabela Cieszykowska,&nbsp;Małgorzata Żółtowska,&nbsp;Dariusz Pawlak,&nbsp;Łukasz Sochaczewski,&nbsp;Zbigniew Tymiński,&nbsp;Justyna Marganiec-Gałązka,&nbsp;Renata Mikołajczak","doi":"10.1016/j.nucmedbio.2025.109595","DOIUrl":"10.1016/j.nucmedbio.2025.109595","url":null,"abstract":"<div><h3>Background</h3><div>Scandium-47 (⁴⁷Sc), a medium-energy β⁻ emitter with a half-life of 3.35 days and associated γ emission (159 keV, 68.1 %), is an attractive radionuclide for targeted radionuclide therapy and theranostics. Production of ⁴⁷Sc via neutron irradiation of enriched ⁴⁶Ca targets through the ⁴⁶Ca(n,γ)⁴⁷Ca → ⁴⁷Sc decay pathway offers advantages such as thermal neutron utilisation and minimised contaminant co-production. Efficient separation and repeated recovery of ⁴⁷Sc in a quasi-generator system are crucial for enabling its medical application.</div></div><div><h3>Results</h3><div>Neutron irradiations of calcium carbonate targets ⁴⁶Ca-enriched (5.2 % and 10.5 %) at the Maria research reactor yielded up to 5.18 GBq ⁴⁷Sc and 5.60 GBq ⁴⁷Ca at the end of bombardment. Separation of ⁴⁷Sc from ⁴⁷Ca was performed using DGA resin with recovery efficiencies of 81–97 % for ⁴⁷Sc and 98–99 % for ⁴⁷Ca in up to five consecutive elutions within 18 days. Radiochemical purity of eluted [⁴⁷Sc]ScCl₃ exceeded 95 % in initial separations. Radiolabelling studies with DOTA-TATE demonstrated effective molar activities up to 20 MBq/nmol and radiochemical purities &gt;98 %. Stability tests confirmed that the [⁴⁷Sc]ScCl₃ eluate remained suitable for radiolabelling for the entire testing period of up to 4 days post-elution. Trace metal analysis showed predominantly low contamination levels, with sporadic impurities attributed to handling conditions.</div></div><div><h3>Conclusions</h3><div>The ⁴⁷Ca/⁴⁷Sc quasi-generator system based on neutron irradiation of enriched ⁴⁶Ca targets offers a reliable source of high-quality ⁴⁷Sc for radiopharmaceutical applications. Multiple elutions from a single target enable sustained production of ⁴⁷Sc with excellent radionuclidic and radiochemical purity. These results support further development of ⁴⁷Sc as a theranostic radionuclide for larger-scale production. A preliminary specification for ⁴⁷Sc as a radionuclide precursor was proposed following the European Pharmacopoeia guidelines, providing a groundwork for future standardisation.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109595"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C–H (radio)fluorination of hydroxamides via strained and electronically tunable α-lactams enabled by N–O scission","authors":"Siran Qian,&nbsp;Surendra Reddy Gundam,&nbsp;Carol Garcia,&nbsp;Shihong Li,&nbsp;Hsiaoju Lee,&nbsp;Jay S. Wright","doi":"10.1016/j.nucmedbio.2025.109594","DOIUrl":"10.1016/j.nucmedbio.2025.109594","url":null,"abstract":"<div><div>Positron emission tomography (PET) fluorine-18 radiosynthesis primarily relies on operationally robust, albeit scope-limited methodologies. Therefore, a marked scientific need remains for new PET-compatible labelling protocols to expand radiochemical space. In this context, α-fluoroamides are a well-established motif in drug molecules that have yet to be extensively adopted for fluorine-18 PET. Accordingly, this Article describes the nucleophilic substitution of amide α-C–H bonds with (radio)fluoride via base-mediated cyclisation of <em>N</em>-sulphonyloxyamides under conditions conducive to PET production. Radiolabelling proceeds with excellent radiochemical conversions (RCC, up to 91%), radiochemical purities (RCP, up to &gt;99%), isolated radiochemical yields (RCY, up to 23%), and molar activities (A_m, up to 85.1 GBq/μmol) under manual and fully automated conditions. Divergent access to ¹⁹F-standards for imaging agent characterisation is efficiently realised under an analogous protocol, which was modified to selectively deliver α-lactams (aziridinones) with unprecedented resistance to decomposition. A fluorination mechanism involving N<img>O scission, lactamisation, and strain-release-driven C<img>N ionisation is proposed. These protocols provide a versatile platform for the radiosynthesis of fluoroamides with high PET production utility.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109594"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of glycoside-based nuclear medicine imaging agents for the sodium–glucose co-transporters in cancer cells","authors":"Kakeru Sato ,&nbsp;Ririka Handa ,&nbsp;Jianwei Yao ,&nbsp;Jinya Higashino ,&nbsp;Taiga Watanabe ,&nbsp;Ryotaro Abe ,&nbsp;Yuna Hamada ,&nbsp;Jundai Yamagata ,&nbsp;Yuma Momose ,&nbsp;Asuka Mizutani ,&nbsp;Masato Kobayashi ,&nbsp;Ryuichi Nishii ,&nbsp;Keiichi Kawai","doi":"10.1016/j.nucmedbio.2025.109591","DOIUrl":"10.1016/j.nucmedbio.2025.109591","url":null,"abstract":"<div><h3>Introduction</h3><div>Sodium–glucose co-transporters (SGLTs), particularly SGLT1 and SGLT2, play an active role in glucose uptake by cancer cells and have gained attention as novel therapeutic targets. However, the development of nuclear medicine imaging agents specific to SGLTs has not yet been explored. This study aimed to develop and evaluate radiolabeled glycoside derivatives targeting SGLT1 and SGLT2 for cancer imaging.</div></div><div><h3>Methods</h3><div>β-Arbutin, a structural analog of methyl-α-D-glucopyranoside (MDG) which is SGLTs substrate, and phlorizin, a SGLT2 inhibitor, were selected as glycoside compounds for radioiodination, [¹²⁵I]β-arbutin and [¹²⁵I]phlorizin were synthesized. The accumulation was measured in HEK293 cells transfected overexpress GLUT1, GLUT3, SGLT1, or SGLT2. Subsequent accumulation studies were conducted in LS180 and DLD-1 cancer cell lines, and the gene expression levels were quantified by real-time polymerase chain reaction (PCR). Biodistribution of both radiotracers was examined in tumor-bearing mice.</div></div><div><h3>Results</h3><div>[¹²⁵I]β-Arbutin had affinity for SGLT1 and SGLT2, whereas [¹²⁵I]phlorizin had affinity for SGLT1 and GLUT3. [¹²⁵I]β-Arbutin accumulated preferentially in SGLT1-high LS180 cells, whereas [¹²⁵I]phlorizin accumulated in GLUT3-high DLD-1 cells. <em>In vivo</em>, [¹²⁵I]β-arbutin exhibited favorable biodistribution with low brain and thyroid accumulation, rapid blood clearance, and high tumor-to-blood ratios in SGLT1-expressing tumors. Although [¹²⁵I]phlorizin also showed low brain and thyroid accumulation, its blood clearance was slower and tumor-to-blood ratios were lower.</div></div><div><h3>Conclusion</h3><div>[¹²⁵I]β-Arbutin is a promising radiopharmaceutical candidate for imaging cancers with high SGLTs expression.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109591"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145691348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rodent biodistribution and dosimetry of the PET radioligands [18F]CHDI-385 and [18F]CHDI-386 targeting mutant huntingtin aggregates","authors":"Jordy Akkermans ,&nbsp;Alan Miranda ,&nbsp;Jeroen Verhaeghe ,&nbsp;Filipe Elvas ,&nbsp;Franziska Zajicek ,&nbsp;Jonathan Bard ,&nbsp;Longbin Liu ,&nbsp;Vinod Khetarpal ,&nbsp;Robert Doot ,&nbsp;Steven Staelens ,&nbsp;Daniele Bertoglio","doi":"10.1016/j.nucmedbio.2025.109601","DOIUrl":"10.1016/j.nucmedbio.2025.109601","url":null,"abstract":"<div><h3>Background</h3><div>Huntington's disease is a neurodegenerative condition resulting from an expanded CAG repeat in the huntingtin gene that produces a mutant form of the huntingtin protein (mHTT). In this study we estimated the radiation safety of two structurally related mHTT radioligands, [¹⁸F]CHDI-385 and [¹⁸F]CHDI-386, by evaluating the <em>in vivo</em> and <em>ex vivo</em> dosimetry of both radioligands using CD-1 Swiss mice.</div></div><div><h3>Methods</h3><div>We used adult male and female CD-1 Swiss mice (<em>n</em> = 15 per sex/radioligand) to assess <em>in vivo</em> positron emission tomography/computed tomography (PET/CT) imaging-based and <em>ex vivo</em> biodistribution-based tracer distribution of the radioligands at 30-, 60-, 120-, 240-, and 360-min post-radioligand injection. Organ activity was quantified, and the residence time was extrapolated to human phantoms. The absorbed and effective doses were estimated using OLINDA/EXM 2.2 and IDAC-Dose2.1.</div></div><div><h3>Results</h3><div>Both radioligands, [¹⁸F]CHDI-385 and [¹⁸F]CHDI-386, showed high uptake in the gallbladder and urinary bladder, with a slow washout in most organs. The colon wall received the highest equivalent organ dose for both modalities. <em>Ex vivo</em> effective dose estimates were 15.4 μSv/MBq for [¹⁸F]CHDI-385 and 16.3 μSv/MBq for [¹⁸F]CHDI-386, while <em>in vivo</em> effective dose estimates were 18.5 μSv/MBq and 18.7 μSv/MBq, respectively.</div></div><div><h3>Conclusion</h3><div>[¹⁸F]CHDI-385 and [¹⁸F]CHDI-386 dosimetry results showed absorbed and effective doses in acceptable range and below the recommended limits. An injection of 370 MBq (10 mCi) in humans is estimated to result in highest (<em>in vivo</em>) effective doses of 6.85 mSv for [¹⁸F]CHDI-385 and 6.92 mSv for [¹⁸F]CHDI-386.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109601"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matched pair suitability of 89Zr and 177Lu-labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma","authors":"Cyril O.Y. Fong ,&nbsp;Ejike V. Iweha ,&nbsp;Fabio Gallazzi ,&nbsp;Anupam Mathur ,&nbsp;Olivia Heyne ,&nbsp;Jodi Mootz ,&nbsp;Madison Mayher ,&nbsp;David S. Tatum ,&nbsp;Darren Magda ,&nbsp;Carolyn J. Anderson","doi":"10.1016/j.nucmedbio.2025.109597","DOIUrl":"10.1016/j.nucmedbio.2025.109597","url":null,"abstract":"&lt;div&gt;&lt;div&gt;There is a need for chelators that are versatile for complexing multiple radiometals. We previously demonstrated that the macrocyclic 1,2-HOPO chelator, L804, has utility for complexing &lt;sup&gt;177&lt;/sup&gt;Lu(III) for radiopharmaceutical therapy and &lt;sup&gt;89&lt;/sup&gt;Zr(IV) for PET imaging with antibody-based agents. Here, we investigated whether &lt;sup&gt;89&lt;/sup&gt;Zr-radiolabelled peptidomimetic LLP2A could function as a diagnostic surrogate for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LLP2A therapy in the targeting of VLA-4 overexpressed in melanoma, with and without an albumin-binding moiety (pIBA) for biological half-life extension.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;L804-LLP2A (&lt;strong&gt;1&lt;/strong&gt;) and L804-pIBA-LLP2A (&lt;strong&gt;2&lt;/strong&gt;) were synthesized and radiolabelled with &lt;sup&gt;89&lt;/sup&gt;Zr and &lt;sup&gt;177&lt;/sup&gt;Lu. Distribution coefficients, in vitro binding affinity, biodistribution, and PET/SPECT imaging data in the B16F10 tumor-bearing mice model of metastatic melanoma were collected.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Quantitative radiochemical yield (&gt;99 %) was achieved with &lt;sup&gt;89&lt;/sup&gt;Zr and &lt;sup&gt;177&lt;/sup&gt;Lu within 30 min at 25 °C. Through a shake flask method, the LogD&lt;sub&gt;7.4&lt;/sub&gt; distribution coefficients of [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; (−0.67 ± 0.06 and − 1.05 ± 0.10, respectively) indicated greater lipophilicity compared to their non-albumin binder containing analogues, [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; (−1.67 ± 0.19 and − 1.26 ± 0.12, respectively). The addition of pIBA to the tracer scaffold did not appreciably affect binding affinity of &lt;sup&gt;89&lt;/sup&gt;Zr- or &lt;sup&gt;177&lt;/sup&gt;Lu-labeled LLP2A to VLA-4, with the K&lt;sub&gt;d&lt;/sub&gt; values for [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; vs [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; (2.2 ± 0.2 vs 1.6 ± 0.2 nM) and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; vs [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; (8.4 ± 1.0 vs 10.8 ± 2.6 nM) being comparable. In B16F10 melanoma tumor-bearing mice, both [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; exhibited rapid blood clearance but had distinctly different biodistribution profiles. [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; was retained more in the tumor, kidney, and spleen out to 48 h compared to [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt;. There was a rapid clearance from both tumor and normal tissues for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; out to 48 h, and aside from the muscle, tumor: non-tumor ratios were overall greater for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; than those obtained for [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt;. The albumin-binding [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; displayed more similar distribution profiles, with higher tumor and non-tumor tissue accumulation, and significantly slower blood clearance. Both tracers gradually cleared out of tumor and non-tumor tissues, although [&lt;sup&gt;","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109597"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outside Back Cover - Graphical abstract TOC/TOC in double column/Cover image legend if applicable, Bar code, Abstracting and Indexing information","authors":"","doi":"10.1016/S0969-8051(25)00597-9","DOIUrl":"10.1016/S0969-8051(25)00597-9","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"150 ","pages":"Article 109588"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in understanding and improving the stability of 211At-radiopharmaceuticals","authors":"Romain Fouinneteau ,&nbsp;Nicolas Galland ,&nbsp;Cécile Perrio ,&nbsp;François Guérard","doi":"10.1016/j.nucmedbio.2025.109573","DOIUrl":"10.1016/j.nucmedbio.2025.109573","url":null,"abstract":"<div><div>Astatine-211 is more than ever a serious candidate radionuclide to achieve success of targeted alpha therapy of cancers in the close future. However, several challenges remain to be overcome in order to guarantee the translation of ²¹¹At-labeled radiopharmaceuticals to the clinic. Particularly, the lack of biological stability of ²¹¹At-labeling, which has been identified in early studies with astatoaryl-based compounds, is still the object of active research. This has led to two main approaches to optimize stability: i) modulation of the astatoaryl moiety, ii) binding astatine to other moieties than phenyl derivatives. In addition, improvement of the knowledge on astatine chemical properties now facilitates the design of optimal structures and opens new perspectives. Hypotheses have also emerged, rationalizing the potential mechanisms at stake in the in vivo degradation of the carbon‑astatine bond and that should facilitate the development of strategies to counter these events. In this work, we discuss the advances made in the stabilization of ²¹¹At-labeling since the last review dedicated to this topic reported by D.S. Wilbur in 2008.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"150 ","pages":"Article 109573"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical evaluation of two new neutrophil elastase inhibitors synthesized by palladium-mediated [11C]cyanations","authors":"Viola Wilson ,&nbsp;Hongchao Zhang ,&nbsp;Sergio Estrada ,&nbsp;Luke R. Odell ,&nbsp;Kim Lambrechts ,&nbsp;Olof Eriksson ,&nbsp;Gunnar Antoni","doi":"10.1016/j.nucmedbio.2025.109179","DOIUrl":"10.1016/j.nucmedbio.2025.109179","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"150 ","pages":"Article 109179"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145473527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}